Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer

US8426571B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Arthur B. Raitano · Los Angeles, US
• Mary Faris · Los Angeles, US
• Pia M. Challita-Eid · Calabasas, US
• Aya Jakobovits · Beverly Hills, US
• Wangmao Ge · Tampa, US

Key dates

• Filing date: Feb 4, 2011
• Grant date: Apr 23, 2013
• Expiry date: Feb 17, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 202P5A5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 202P5A5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 202P5A5 can be used in active or passive immunization.